Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
James L. Kirkland, MD, PhD
To determine whether short-term treatment with Fisetin reduces the rate of death and long term complications related to COVID-19 and to determine the safety of treatment with Fisetin in this patient population.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females, at least 18 years of age, capable and willing to provide informed consent;
Patient must have received a diagnosis of COVID-19 infection within the last 3 days;
Outpatient setting (not currently hospitalized);
Patient must possess at least one of the following high-risk criteria: 60 years or more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma, chronic obstructive pulmonary disease, or present or past smoking), known heart failure, known coronary disease, fever of ≥38.4°C within the last 48 hours, dyspnea at the time of presentation, the combination of high neutrophil count and low lymphocyte count;
Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion;
Patient or their caregiver must be able and willing to comply with the requirements of this study protocol.
You may not be if
Patient currently hospitalized or under immediate consideration for hospitalization;
Patient currently in shock or with hemodynamic instability;
Patient with severe hepatic disease (as per clinical judgement) and liver enzymes \>10x the upper limit of normal;
Female patient who is pregnant, breast-feeding, or is considering becoming pregnant during the study or for 1 day after the last dose of study medication;
Patient currently taking Sirolimus, Tacrolimus, or other mTOR inhibitors for other indications (mainly chronic indications represented by organ transplantation or autoimmune diseases);
On Warfarin therapy;
Patient with a history of an allergic reaction or significant sensitivity to Fisetin;
Patient undergoing chemotherapy for cancer;
Patient is considered by the investigator, for any reason, to be an unsuitable study candidate.
Clareo Health | COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications
